Compositions For Biomedical Applications

• US 20100159011A1
• Filed: 07/31/2008
• Published: 06/24/2010
• Est. Priority Date: 08/03/2007
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Ayers, David C., Li, Xinning, Song, Jie, Lian, Jane B.
• Application Number:
  US12/183,293
• Publication Number:
  US 20100159011A1
• Time in Patent Office: Days
• US Class Current: 424/487
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/46 with phosphorus-containing inorganic fillers
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: C08G 77/045 containing less than 25 silicon atoms
• CPC Class Codes: C08G 77/38 Polysiloxanes modified by chemical after-treatment C08G77/045 takes precedence
• CPC Class Codes: C08G 77/445 containing polyester sequences

Abstract

The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules.

Claims

1. A composite material comprising:

a) a polymer matrix comprising a polymer comprising monomer subunits comprising hydroxyl groups, wherein said monomers are linked via a covalent linkage comprising polyethylene glycol subunits;

b) calcium phosphate aggregates distributed within said polymer matrix; and

c) a biomolecule.

2. The material of claim 1, wherein said biomolecule is selected from the group comprising peptides, proteins, recombinant proteins, saccharides, and nucleic acids.

3. The material of claim 1, wherein said biomolecules are growth factors.

4. The material of claim 1, wherein said biomolecules are selected from the group consisting of BMP-2, BMP-2/7, RANKL, and VEGF.

5. The material of claim 1, wherein said biomolecules comprise a peptide with SEQ ID:

1.

6. The material of claim 2, wherein said nucleic acid is a gene vector.

7. The material of claim 6, wherein said gene vector encodes a protein selected from the group consisting of BMP-2, BMP-2/7, RANKL, and VEGF.

8. The material of claim 1, wherein said monomer subunits are substituted or unsubstituted hydroxyalkyl acrylate subunits.

9. The material of claim 1, wherein said monomer subunits are 2-hydroxyethyl methacrylate subunits.

10. The material of claim 1, wherein said calcium phosphate aggregates are selected from the group consisting of calcium hydroxyapatite, and carbonated hydroxyapatite, and beta-tricalcium phosphate.

11. The material of claim 1, wherein said material is between 10%-90% by weight calcium phosphate aggregates distributed within said polymer matrix.

12. A porous composite material comprising:

a) a polymer matrix comprising a polymer comprising monomer subunits comprising hydroxyl groups,

wherein said monomers are linked via a covalent linkage comprising polyethylene glycol subunits;

b) calcium phosphate aggregates distributed within said polymer matrix; and

c) cells.

13. The material of claim 12, further comprising a biomolecule selected from the group consisting of growth factors, cytokines, and gene vectors.

14. The material of claim 12, wherein said cells are bone marrow stem cells.

15. The material of claim 12, wherein said pores are as large as 90% of the outer diameter of the material.

16. A method comprising:

a) providing a composite material comprising;

i) a polymer matrix comprising a polymer comprising monomer subunits comprising hydroxyl groups, wherein said monomers are linked via a covalent linkage comprising polyethylene glycol subunits, and

ii) calcium phosphate aggregates distributed within said polymer matrix;

b) creating pores in said composite material providing a porous material;

c) mixing said porous material with a component selected from the group consisting of cells and biomolecules providing a loaded composite; and

d) implanting said loaded composite into a subject.

17. The method of claim 16, wherein said cells are bone marrow cells.

18. The method of claim 17, wherein said biomolecule is selected from the group consisting of growth factors, cytokines, and gene vectors.

19. The method of claim 18, wherein said subject is a selected from the group consisting of a human, mouse, rat, dog, cat, rabbit, pig, horse, and ape.

20. A material composition made by

a) providing,

i) a polymer matrix comprising:

A) a polymer comprising 2-hydroxyethyl methacrylate subunits, wherein said monomers are linked via a covalent linkage comprising polyethylene glycol subunits,

B) calcium phosphate aggregates distributed within said polymer matrix; and

ii) a biomolecule;

b) mixing said polymer matrix and said biomolecule under conditions such that said biomolecule is absorbed to said material.

21. The material of claim 20, wherein said calcium phosphate aggregates are selected from the group consisting of calcium hydroxyapatite, and carbonated hydroxyapatite, and beta-tricalcium phosphate.

22. The material of claim 20, wherein said calcium phosphate aggregates have a size between 50 nanometers and 500 micrometers.

23. The material of claim 20, wherein said calcium phosphate aggregates are between 30%-70% by weight of said material.

24. The material of claim 20, wherein said calcium phosphate aggregates are between 10%-90% by weight of said material.

25. A composite material comprising:

a) a polymer matrix comprising a polymer comprising monomers of 2-hydroxyethyl methacrylate subunits, wherein said monomers are linked via a covalent linkage comprising polyethylene glycol subunits;

b) calcium phosphate aggregates distributed within said polymer matrix; and

c) a peptide.

26. The composite of claim 25, wherein said peptide is selected from the group consisting of a protein and recombinant proteins.